Form D · Biotechnology
Antidote Therapeutics, Inc.
Gaithersburg, MD · CIK 0001716110
Offering snapshot reported Sep 11, 2017 · SEC filing
- Reported sold
- $200K Offering amount: $200K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 6, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 11, 2017 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Sep 5, 2017 | Initial | $432,341 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-294374
Source: Form D, filed Sep 11, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth C. Carter | Director |
| Matthew W. Kalnik, Ph D | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
708 Quince Orchard Road Suite 250 C
Gaithersburg, MD, 20878
Gaithersburg, MD, 20878